Boehringer Ingelheim is pumping funds into the still-hot antibody-drug conjugate space, committing 27 million Swiss francs ...

Lake Street analyst Chad Messer initiated coverage of Immunome (IMNM) with a Buy rating and $23 price target The company’s lead clinical ...

Sutro Biopharma, Inc.’s STRO share price has dipped by 10.88%, which has investors questioning if this is right time to buy.

SUZHOU, China, March 27, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a biopharmaceutical company dedicated to developing innovative cancer therapies, today reported 2024 annual ...

First patient dosed in Phase 1 clinical trial evaluating IM-1021, a ROR1-targeted ADC. IND submitted in March 2025 for IM-3050, a FAP-targeted radioligand therapy. Projected cash runway extends into ...

First patient dosed in Phase 1 clinical trial evaluating IM-1021, a ROR1-targeted ADC. IND submitted in March 2025 for IM-3050, a FAP-targeted radioligand therapy. Projected cash runway extends ...

Sutro Biopharma, Inc. announced a strategic shift focusing on its next-generation exatecan and dual-payload antibody drug conjugate (ADC) programs, deprioritizing the development of luveltamab ...

IM-1021 is an optimized, ROR1-targeted ADC that incorporates Immunome’s proprietary TOP1 inhibitor, HC74. The Phase 1 trial is an open-label, multicenter dose escalation and expansion study designed ...

BOTHELL, Wash., March 10, 2025--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today ...

The existing data underscore its broad potential in both lymphomas and solid tumors. Notably, a ROR1 ADC combined with R-CHP has demonstrated an impressive complete response (CR) rate in a Phase II ...